SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-015395
Filing Date
2021-11-10
Accepted
2021-11-10 08:01:08
Documents
48
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ewtx-20210930x10q.htm   iXBRL 10-Q 2133388
2 EX-31.1 ewtx-20210930xex31d1.htm EX-31.1 17140
3 EX-31.2 ewtx-20210930xex31d2.htm EX-31.2 17414
4 EX-32.1 ewtx-20210930xex32d1.htm EX-32.1 11477
  Complete submission text file 0001558370-21-015395.txt   5873735

Data Files

Seq Description Document Type Size
5 EX-101.SCH ewtx-20210930.xsd EX-101.SCH 27842
6 EX-101.CAL ewtx-20210930_cal.xml EX-101.CAL 29123
7 EX-101.DEF ewtx-20210930_def.xml EX-101.DEF 125587
8 EX-101.LAB ewtx-20210930_lab.xml EX-101.LAB 302475
9 EX-101.PRE ewtx-20210930_pre.xml EX-101.PRE 225838
10 EXTRACTED XBRL INSTANCE DOCUMENT ewtx-20210930x10q_htm.xml XML 838399
Mailing Address 3415 COLORADO AVE. BOULDER CO 80303
Business Address 3415 COLORADO AVE. BOULDER CO 80303 303-735-8373
Edgewise Therapeutics, Inc. (Filer) CIK: 0001710072 (see all company filings)

IRS No.: 821725586 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40236 | Film No.: 211394483
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences